AIMT News and Press, Aimmune Therapeutics Inc. From 02/25/20

Nine Abstracts Will Highlight Data Including on the First FDA-Approved Treatment for Peanut Allergy and Oral Immunotherapy Practice Implementation in a Real-World Setting Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments f...

Ballard Power Systems (NASDAQ: BLDP ) -15% . More news on: Ballard Power Systems Inc., DPW Holdings, Inc., Plug Power Inc., Stocks on the move, , Read more ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, February 27, 2020, at 4:30 p.m. ET to discuss its financial result...

Aimmune ( AIMT ) announced that it had received FDA approval for its peanut allergy drug known as PALFORZIA. It was approved to treat patients with peanut allergy. The goal of its drug is to prevent any issues that may arise from allergic reactions including anaphylaxis. This FDA approval is...

Aimmune Therapeutics Inc (NASDAQ: AIMT) -- a California-based biotechnology company -- recently made history. The company's drug Palforzia became the first treatment for peanut allergies to be approved by the U.S. Food and Drug Administration (FDA). Naturally, investors received the news w...

Aimmune Therapeutics (NASDAQ: AIMT) recently announced a $200 million cash injection from Nestle  (OTC: NSRGY) , the world's largest food and beverage company. The company that produces heaps of peanut-containing products will buy enough common and preferred shares to raise its v...

Myomo (NYSEMKT: MYO ) +93%  on insurance coverage of MyoPro in Germany. More news on: Myomo, Inc., VIVUS, Inc., Camber Energy, Inc., Stocks on the move, , Read more ...

Aimmune Therapeutics (NASDAQ: AIMT ) perks up  10%  premarket on average volume in reaction to its announcement that Nestlé Health Science will invest an additional $200M in the company, raising its stake to $473M (25.6% stake). More news on: Aimmune Therapeutics, Inc., Xe...

~Nestlé Health Science to Purchase Common and Convertible Preferred Aimmune Stock Bringing Total Investment in Aimmune to $473 Million to Date~ Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threa...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb ...